Zofran

Description Ondansetron Hydrochloride, per 1 mg Zfran ; Oprelvekin Newmega ; 5 mg Orphenadrine Citrate, up to 60 mg Other Hemophilia Clotting Factors e.g., anti-inhibitors ; Oxacillin Sodium, up to 250 mg Bactocile, Prostaphlin ; Oxymorphone HCL, up to 1 mg Oxytetracycline HCL, up to 50 mg Terramycin IM ; Oxytocin, up to 10 units Pitocin, Syntocinon ; Paclitaxel, 30 mg Taxol ; Pamidronate Disodium, per 30 mg Aredia ; Papaverine HCL, up to 60 mg Pegaspargase Onscospar ; Single Dose vial 5 ml SDV Penicillin G Benzathine and Penicillin G Procaine, up to 1, 200, 000 units Penicillin G Benzathine and Penicillin G Procaine, up to 2, 400, 000 units Penicillin G Benzathine and Penicillin G procaine, up to 600, 000 units Penicillin G Benzathine, up to 1, 200, 000 units Bicillin L-A, Permapen ; Penicillin G Benzathine, up to 2, 400, 000 units Bicillin L-A, Permapen ; Penicillin G Benzathine, up to 600, 000 units Bicillin L-A, Permapen ; Penicillin G Potassium, up to 600, 000 units Penicillin G Procaine, Aqueous, up to 600, 000 units Pentagastrin, per 2 ml Peptavlon ; Pentamidine Pentam 300 ; Pentamidine Isethionate Pentazocine HCL, up to 30 mg Talwin ; Pentobarbital Sodium Nembutal Sodium Solution ; 50 mg Pentostatin, 10 mg Piperacillin Sodium 4 gm Pipracil ; Perphenazine, up to 5 mg Trilafon ; Phenobarbital Sodium, up to 120 mg Phentolamine Mesylate, up to 5 mg Regitine ; Phenylephrine HCL, up to 1 ml NeoSynephrine ; Phenytoin Sodium Dilantin ; Plicamycin, Mithracin ; 2.5 mg Porfimer Sodium 75 mg Potassium Chloride 2 meq. Pralidoxime Chloride, up to 1 gm Protopam Chloride ; Prednisolone Acetate, up to 1 ml Prednisolone Sodium Phosphate, to 20 mg Prednisolone Tebutate, up to 20 mg Procainamide HCL, up to 1 gm Pronestyl ; Prochlorperazine Edisylate 10 mg Compazine, Cotranzine, Compa-Z, Ultrazine-10 Progesterone, per 50 mg Promazine HCL, up to 25 mg Sparine, Prozine-50 ; Promethazine HCL, up to 50 mg Phenergan, Phenazine ; Propiomazine HCL, up to 20 mg Propranolol HCL, up to 1 mg Inderal.

Open Discussion Marty Fuller inquired about Phenergan. He reported in hospital use has followed Phenergan with Benadryl. Dr. Lindstrom reported for EMS this is not an issue, if the patient has a patent line and properly infused, the hospital has more of an issue and the administering of Benadryl prophylactically for extra pyramidal prevention which is not in the protocols. Dr. Lindstrom reported the issue of sedation of the elderly is a concern. Dr. Miramontes suggested the use of Zofgan in lieu of Phenergan and it comes in a generic form. Rich Ellett reported Maumee had problems with their inverter in their rig which was replaced and the problem was corrected. Rich also mentioned they also have an airbag issue which the county garage is looking into. Gary Orlow reported it was a quality issue with recent productions. Dr. Lindstrom asked the paramedics present if there are any issues regarding the lockers at the hospitals. Jeff Nissen reported Bay Park does not stock as much as other hospitals. If they need something that isn't there, they go to St. Charles or St. Vincents. Rich Ellett noted that he has observed non ALS personnel ge tting into the lockers. He has also noted expired medications in the lockers as much as 3-4 months old. He has noted it's a frequent problem at St. Luke's. Rich reported he didn't think it was an annex issue, he thinks squads find expired meds and just put them in the lockers and take new. Tim Treadaway reported he noticed the billing issue discussed in December's minutes and asked if there was an update. Chief McNutt reported this was discussed at the last Policy Board meeting and the Commissioners has put this on hold this year. Tim also asked are there any projections on how much money this would generate. Dennis Cole reported no data on that and he is working with Toledo Fire to get estimates of revenue generation. Dr. Miramontes reported Dennis could check with St. Vincent St. Charles billing MBI and they could give an idea by the number of runs generated. From these guidelines it is apparent that central to the success of the programme is the methodology for correct identification of the reproductive potential of bulls and cows. The main methods are: Behavioural records. Ultra-sonographic examinations. Hormone profiles from blood, faeces or urine ; . Semen quality in males.
Effective April 1, 2007 June 30, 2007 Nexium Tab 40 mg Nitro-Dur Patch 0.2 mg Nitro-Dur Patch 0.6 mg Nitro-Dur Patch 0.8 mg Norflex Tab 100 mg Norgesic Tab 25 mg Norgesic Forte Tab 50 770 60 mg Parlodel Tab 2.5 mg Parlodel Cap 5 mg Paxil CR Tab 12.5 mg Paxil CR Tab 25 mg Permax Tab 0.05 mg Permax Tab 0.25 mg Permax Tab 1 mg Plaquenil Tab 200 mg Plavix Tab 75 mg Plendil Tab 2.5 mg Plendil Tab 5 mg Plendil Tab 10 mg Pravachol Tab 40 mg Premarin Tab 0.3 mg Premarin Tab 0.625 mg Premarin Tab 0.9 mg Premarin Tab 1.25 mg Prevacid Cap 15 mg Prevacid Cap 30 mg Prograf Cap 0.5 mg Prograf Cap 1 mg Prograf Cap 5 mg Prozac Cap 10 mg Prozac Cap 20 mg Pulmicort Turbuhaler 200 mcg Remeron Tab 30 mg Risperdal Tab 0.25 mg Risperdal Tab 0.5 mg Risperdal Tab 1 mg Risperdal Tab 2 mg Risperdal Tab 3 mg Risperdal Tab 4 mg Rythmol Tab 150 mg Rythmol Tab 300 mg Seroquel Tab 25 mg Seroquel Tab 100 mg Seroquel Tab 200 mg Seroquel Tab 300 mg Sinemet CR Tab 200 50 mg Singulair Chew Tab 4 mg Singulair Chew Tab 5 mg Soriatane Cap 10 mg Soriatane Cap 25 mg Spiriva Cap 18 mcg with HandiHaler ; Tambocor Tab 50 mg Tambocor Tab 100 mg Tapazole Tab 5 mg Tofranil Tab 50 mg Topamax Tab 25 mg Topamax Tab 100 mg Topamax Tab 200 mg Ultravate Cream 0.05% Uniphyl Tab 400 mg Uniphyl Tab 600 mg Valtrex Caplets 500 mg Wellbutrin SR Tab 100 mg Wellbutrin SR Tab 150 mg Wellbutrin XL Tab 150 mg Wellbutrin XL Tab 300 mg Xeloda Tab 150 mg Xeloda Tab 500 mg Zaroxolyn Tab 2.5 mg Zocor Tab 20 mg Zocor Tab 40 mg Zocor Tab 80 mg Zof5an Tab 4 mg Zofra Tab 8 mg Zyban Tab 150 mg Zyprexa Tab 2.5 mg Zyprexa Tab 5 mg Zyprexa Tab 7.5 mg Zyprexa Tab 10 mg Zyprexa Zydis Tab 5 mg Zyprexa Zydis Tab 10 mg. The French research team launched this small clinical trial in hopes of finding more answers. Each person who enrolled was assigned at random to a group receiving 4 mg of Zofram twice each day, or a group receiving a placebo, an intervention used as a comparison in clinical trials but which has no therapeutic effectiveness. Nearly all the people involved considered fatigue their most significant symptom of the disease, and nearly twothirds considered it their worst, the researchers noted. Neither the individuals nor the clinicians in the study knew who was taking Zofran, and who was not, to eliminate any possible bias. One potential side effect of the medication is constipation, but people were treated using a laxative, if necessary. The trial lasted four weeks. During that time, levels of fatigue and depression were measured regularly using questionnaires completed by each person. After one month of treatment, people then underwent observation for four weeks. BIOPERINE - The metabolic process that generates energy at the cellular level in our body is called thermogenesis. While thermogenesis has typically been categorized as a key factor in weight loss, to confine the scope of its function to this aspect alone is incomplete. Thermogenesis plays an integral role in our body's ability to properly utilize the daily foods and nutrients we take in. It sets in motion the mechanisms that lead to digestion and subsequent gastrointestinal absorption. Piperine, in the patented form of Bioperine enhances the body's natural thermogenic activity - hence the term Thermonutrient. This enhancement may be explained as a means of increasing thermal energy sufficient to "power up" mechanisms related to thermogenesis. This in turn results in increased metabolic processes that create a "demand" for "supply" of a broad range of nutrients that contribute to metabolism. Bioperine, a patented compound is derived from the Piper Nigrum pepper plant and acts in many ways like Cayenne does see above ; . It boosts circulation because of the thermogenesis effect and in turn, turbo charges all other ingredients to work on a higher level and reminyl.
Hepatobiliary: Liver enzyme abnormalities have been reported. Liver failure and death have been reported in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear. Local Reactions: Pain, redness, and burning at site of injection. Lower Respiratory: Hiccups Neurological: Oculogyric crisis, appearing alone, as well as with other dystonic reactions. Skin: Urticaria Special Senses: Transient dizziness during or shortly after I.V. infusion. Eye Disorders: Transient blurred vision, in some cases associated with abnormalities of accommodation. Cases of transient blindness, predominantly during intravenous administration, have been reported. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. DRUG ABUSE AND DEPENDENCE Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies. OVERDOSAGE There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. Individual doses as large as 150 mg and total daily dosages three doses ; as large as 252 mg have been administered intravenously without significant adverse events. These doses are more than 10 times the recommended daily dose. In addition to the adverse events listed above, the following events have been described in the setting of ondansetron overdose: "Sudden blindness" amaurosis ; of 2 to minutes' duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension and faintness ; occurred in another patient that took 48 mg of oral ondansetron. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed. In all instances, the events resolved completely. DOSAGE AND ADMINISTRATION Prevention of Chemotherapy-Induced Nausea and Vomiting: Adult Dosing: The recommended I.V. dosage of ZOFRAN for adults is a single 32-mg dose or three 0.15-mg kg doses. A single 32-mg dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. The recommended infusion rate should not be exceeded see OVERDOSAGE ; . With the three-dose 0.15-mg kg ; regimen, the first dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. Subsequent doses 0.15 mg kg ; are administered 4 and 8 hours after the first dose of ZOFRAN. ZOFRAN Injection should not be mixed with solutions for which physical and chemical compatibility have not been established. In particular, this applies to alkaline solutions as a precipitate may form. 21. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized in Table 4: Table 4. Emetic Episodes: Treatment Response Ondansetron Number of patients 8-mg b.i.d. ZOFRAN Tablets * 165 8-mg t.i.d. ZOFRAN Tablets 171 and revia.

To mood disorder in climacteric women and to clarify the relationship between immune function and the efficacy of herbal medicine, we compared serum TNF-alpha levels in two treated groups, with and without concurrent use of herbal medicine. This study included 113 consecutive depressed menopausal patients who visited the gynecological and psychosomatic medicine outpatient clinic of the Osaka Medical College Hospital in Japan. Fifty-eight patients were administered kami-shoyo-san according to the definition of above sho. In contrast, 55 patients who were different in sho of kami-shoyo-san were administered antidepressants. Hamilton Rating Scale for depression HAM-D ; scores were determined at baseline and 12 weeks after starting treatment endpoint ; . TNF-alpha concentrations were analyzed before and after 12 weeks of treatment. Kami-shoyo-san significantly increased plasma concentrations of TNF-alpha after 12 weeks of treatment, to 17.22 + - 6.13 pg ml from a baseline level of 14.16 + - 6.27 pg ml p 0.048 ; . The percent change in plasma concentration of TNF-alpha differed significantly between the kami-shoyo-san therapy group and the antidepressant therapy group at 4 weeks 12.0 + - 7.8% and -1.22 + - 0.25%, respectively, p 0.01 ; , 8 weeks 19.7 + - 3.4% and -2.45 + - 0.86%, respectively, p 0.01 ; , and 12 weeks 21.3 + - 5.4% and -6.81 + - 2.2%, respectively, p 0.001 ; . We found in this study that kami-shoyo-san, an herbal medicine, increased plasma TNF-alpha levels in depressed menopausal patients. Cytokines may play various roles in mood and emotional status via the central nervous system and may be regulated by herbal medicines, although the interactions are very complex. For orbitotomy, transcranial approach, see 61330-61334 ; For orbital implant, see 67550, 67560 ; For optic nerve sheath decompression, see 67570 ; For removal of eyeball or for repair after removal, see 65091-65175 ; OTHER PROCEDURES 67500 67505 67515 Retrobulbar injection; medication separate procedure, does not include supply of medication ; alcohol Injection of medication or other substance into Tenon's capsule For subconjunctival injection, see 68200 ; 40.00 + T 3.0 + T and dramamine. Syndrome in which QT prolongation is associated with torsade de pointes and sudden cardiac death for review, see Priori et al., 1999 ; . Drugs that block K channels may produce QT prolongation, whereas drugs that block Na channels may produce widening of QRS and in both cases ventricular arrhythmias may result. Antagonists of the 5-HT3 serotonin receptor are widely used in the treatment of postoperative and chemotherapyinduced nausea and vomiting. Clinically available drugs are granisetron Kytril ; , ondansetron Zofran ; , and dolasetron Anzemet ; . In addition to block of 5-HT3 receptors, these drugs have been reported to widen the QRS complex and prolong JT, QT, and PR intervals Benedict et al., 1996; Jantunen et al., 1996; Boike et al., 1997 ; . For example, dolasesetron 1.2 4.0 mg kg i.v. ; can prolong QRS by 5 to 20%, whereas ondansetron has been shown to increase QT and JT intervals by an average of 2 to 5% Hunt et al., 1995; Benedict et al., 1996; Boike et al., 1997 ; . To understand better the ECG changes associated with administration of granisetron, ondansetron, and dolasetron we examined their effects of on hH1, HERG, and KvLQT1 minK.
Table 3-5. Conversion of Native Utilities continued ; Features Likelihood that file exists in TOC but not in archive tar Low cpio Low dump Medium since TOC is made first and parlodel.

Of 22 sham-controlled studies and more than 2, 000 patients on the efficacy of acupuncture for smoking cessation, found no evidence for therapeutic acupuncture for smoking cessation. Sham-controlled studies on conventional acupuncture, acupressure, electroacupuncture, and laser acupuncture were included in the meta-analysis White, Rampes, & Ernst, 2004.
Dosage Forms Pharmorubicin 10mg vial CEPIRU1 Pharmorubicin 50mg vial CEPIRU2 Use Breast cancer, bladder cancer, endometrial cancer, lung cancer, ovarian cancer nasopharyngeal carcinoma, soft-tissue sarcomas Dose IV: 60-90mg m2 every 3 wks over 3-5 min ; Adverse Reactions Myelosuppression, cardiomyopathy or CHF, arrythmias, alopecia, nausea, amenorrhea, vomiting Precautions 1. Further dilutions in D5W or NS is stable for 24 hrs at room temperature and 48 hrs at refrigeration 2. Max cumulative dose: 550-900mg m2 3 and hydrea!

NDSU faculty are invited to participate in a luncheon scheduled for 11: 45 a.m. Thursday, Sept. 21, in the Memorial Union Ballroom. The event will recognize faculty from the Department of Health, Physical Education and Recreation for their work with assessment activities. It is also an opportunity for faculty to learn about assessment practices used in the department. A sandwich buffet will begin at 11: 45 a.m. and all activities will be concluded by 1 p.m. Bradford Strand, chair and professor of health, physical education and recreation, will present "Seven Steps to Successful Assessment" and initiate discussion of how assessment activities are organized in his department. This short presentation will be followed by a question-and-answer session conducted by the faculty of the HPER department. The luncheon is sponsored by the members of the University Assessment Committee as part of a series of events made possible by a grant from the Bush Foundation. Susan Hatfield, assessment of student learning expert from Winona State University, will return to NDSU to serve as a consultant with colleges and departments on assessment practices and to present an open forum on assessment. Hatfield is scheduled to visit NDSU Oct. 16-18. As her visit to NDSU approaches, the University Assessment Committee will invite departments and colleges to schedule time to meet with her and discuss their activities and objectives in assessing student learning. Suggestions for topics for future assessment luncheons may be submitted at the luncheon to any member of the University Assessment Committee, or by calling 1-8262. Members of the University Assessment Committee include: Strand; Richard Chenoweth, director of summer school; Bob Harrold, professor of animal and range sciences; Allyn Kostecki, director of TRIO programs; Mary Kuzel, assistant professor of pharmacy; Joe Latimer, instructor of business administration; Jeff Low, clinical assistant professor of pharmacy; Jim Lindley, associate professor of ag and biosystems engineering; Bill Martin, assistant professor of mathematics; Ines Rothe, graduate student in plant sciences; J.W. Schroeder, extension specialist in animal and range sciences; Richard Shaw, associate professor of English; and William Slanger, director of institutional analysis.
Nitroglycerin, 23, 161 Nonprescription analgesics. See Over-the-counter analgesics. Nonsteroidal anti-inflammatory agents NSAIDs ; for coexisting migraine and tension-type headaches, 145 contraindications for, 175 for migraines, 93-94, 96 as abortive therapy, 93-94 in elderly, 161 in emergency patients, 199 menstrual, 171, 174 for pain relief, 96 as prophylactic therapy, 100t-101t, 104-105 monitoring use of, 160-161 for tension-type headaches, 137, 139 Norepinephrine, effects of antidepressants on, 140t-141t Norflex. See Orphenadrine. Nortriptyline, 100t, 139, 140t Nose diseases, headache and, 12t examination, 26, 192 NSAIDs. See Nonsteroidal anti-inflammatory agents. Nuchal area, pain in, 47 Nuchal rigidity, 28t, 151 Obesity, 152-153 Obstetric history, 24 Occipital headache, 34, 40, 155 Occipital neuralgia, post-traumatic, 183 Occiput, pain in, 47 Occlusive vascular disease, 12t Ocular motor paralysis, 46 Oculosympathetic paresis, 187 Ondansetron Zofran ; , 92, 97, 200t Onset of headaches, 14t, 20. See also specific headache type. recent onset, viii, 33, 45, 150, Ophthalmic causes of headaches in children, 151 Ophthalmoplegia, 46 Ophthalmoplegic basilar artery headache, 12t, 155-156 Ophthalmoplegic migraine, 60, 155 Opiates, 142 Optic nerve injuries, 187 Oral contraceptives OCs ; , 25, 59, 168, Oral hypoglycemics, 99 Orbital cellulitis, 150 Organic disease and associated headaches. See Organic headaches. Organic headaches, 33-54. See also specific organic conditions. characteristics and symptoms, 22, 34 in children, 150-153 and zometa. Thomas W. Arnold Deputy Secretary for Medicaid TWA: cb Enclosure. Proper drug therapy management in the elderly is an important issue for both primary care providers and specialists caring for these people. Addressing and lamictal and Zofran online. Evidence-based classifications of recommendations The evidence found in the literature research and data extraction was summarised and categorised to reflect its susceptibility to bias Shekelle 1999 ; . Daily treatment costs were not taken into consideration due to the variability of medication costs worldwide. Each treatment recommendation was evaluated and discussed with respect to the strength of evidence for its efficacy, safety, tolerability and feasibility. It has to be kept in mind that the strength of recommendation is due to the level of efficacy and not necessarily of its importance. Four categories were used to determine the hierarchy of recommendations related to the described level of evidence ; : Level A. There is good research-based evidence to support this recommendation. The evidence was obtained from at least three moderately large, positive, randomised controlled double-blind ; trials RCTs ; . In addition, at least one of these three studies must be a well-conducted, placebo-controlled study. Level B. There is fair research-based evidence to support this recommendation. The evidence was obtained from at least two moderately large, positive, randomised, double-blind trials this can be either two or more comparator studies or one comparatorcontrolled and one placebo-controlled study ; or.
If your nausea feeling of sickness ; or vomiting does not go away, ask your doctor what to do. In certain illnesses and treatments where Zofran has been used, blood vessel blockage has occurred. Zofran Suppositories Issue No. 4 and nitrofurantoin.

Zofran information BLS: 1. Initiate General Patient Care. ILS: 2. If patient is greater than 35 years of age, a female in her childbearing years, or suffering from nausea vomiting, attempt Vascular Access. 3. If vital signs and patient's condition indicate hypoperfusion, administer initial fluid challenge of 500 ml NS. If patient's condition does not improve, administer additional challenges as needed, not to exceed 2, 000 ml. Pediatric fluid bolus is 20 ml kg. May repeat as clinically indicated to a maximum of 80 ml kg. ALS: 4. If patient is greater than 35 years of age or has a history of cardiac disease, place on cardiac monitor. 5. If patient complains of nausea vomiting, consider Ondansetron HCl Zofran ; 4 mg slow IV IM. May repeat dose one time as indicated. Pediatric dose of Ondansetron HCl Zofran ; is 0.15mg kg IV IM, not to exceed 4 mg. Recommended for use in children 2 years of age or greater ; 6. Consider Morphine Sulfate 0.1 mg kg slow IV to a maximum single dose of 10 mg. May repeat at 5 minute intervals until pain is relieved or respiratory mental status depression occur. Morphine not recommended for use in children for abdominal pain. 7. Continue General Patient Care. EXECUTIVE BODY 1. Principal Director 2. Director of Health 3. State Tuberculosis Officer 4. Chief Accounts Officer 5. Dist. Tuberculosis Officer HQ ; 6. State I.E.C. Officer 7. Medical Specialist. 1. Consider crush syndrome if the patient has a trapped extremity or torso with compression and compromise of vascular supply that has lasted more 60 minutes. 2. Initiate protocol treatment items 2-5 below ; prior to removal of compression mechanism. 3. Consider any ECG change to be a sign of instability. Any ECG change warrants immediate treatment with calcium chloride.

Zofran tabs Abstract--Type 2 diabetes is a worldwide increasing disease resulting from the interaction between a subject's genetic makeup and lifestyle. In genetically predisposed subjects, the combination of excess caloric intake and reduced physical activity induces a state of insulin resistance. When beta cells are no longer able to compensate for insulin resistance by adequately increasing insulin production, impaired glucose tolerance appears, characterized by excessive postprandial hyperglycemia. Impaired glucose tolerance may evolve into overt diabetes. These 3 conditions, ie, insulin resistance, impaired glucose tolerance, and overt diabetes, are associated with an increased risk of cardiovascular disease. Because all these conditions are also accompanied by the presence of an oxidative stress, this article proposes oxidative stress as the pathogenic mechanism linking insulin resistance with dysfunction of both beta cells and endothelium, eventually leading to overt diabetes and cardiovascular disease. This hypothesis, moreover, may also contribute to explaining why treating cardiovascular risk with drugs, such as calcium channel blockers, ACE inhibitors, AT-1 receptor antagonists, and statins, all compounds showing intracellular preventive antioxidant activity, results in the onset of new cases of diabetes possibly being reduced. Arterioscler Thromb Vasc Biol. 2004; 24: 1-8. ; Key Words: oxidative stress insulin resistance impaired glucose tolerance diabetes cardiovascular disease statins ACE inhibitors AT-1 blockers glitazones calcium channel blockers. Zofran hydrochloride Secondary: Diaphragms, latex condoms, and cervical caps.Each must be used with a spermicide, which is a special cream or jelly that kill sperm. I understandthat at least one of my two methods of birth control must be a primary method. Initial and buy reminyl. All non-Medicare eligible retirees enrolled in the Kaiser medical program who elect to receive prescription benefits will receive their prescription benefit through Kaiser Permanente. Medicare members must elect prescription coverage and have a different co-pay structure. Kaiser Permanente has filed with Medicare to be a Medicare Part D provider. Enrollment in the RETIREE BENEFIT PLAN SUMMARY. Zofran medicine

MEDICATIONS Check only desired orders ; Tylenol 650mg po q6hrs prn temp 100.5, call MD if temp 103. Benadryl 25mg po q6h prn puritis and 25 mg po qhs prn insomnia Ambien 5mg po qhs prn insomnia, may repeat in 1 hr necessary for insomnia Phenergan mg PO IV IM q4h prn nausea vomiting Zofran 4mg IV q 4h prn N V not alleviated by Phenergan Max 2 doses ; Antibiotic q x doses Morphine mg IV q hr prn pain Oxycontin mg po q hr prn pain Oxycontin mg po q hr around the clock Percocet 5 325mg tab po q6h prn breakthrough pain Toradol 30 mg IV q6h x one dose 4 doses NOT PRN if 65 yoa 15 mg IV q6h ; Oxycontin mg po x 1 dose not prn Labs Tests Consults Check only desired orders ; Physical Therapy Consult for Crutches for discharge Follow up appointment in office as scheduled Call for appointment.

Zofran drug interactions